GlassScriptPhysician profile
George A Nasser
NPI 1992880595
$19,213.98
in general payments reported to CMS, 2019-2025
42 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,572 · 2020: $3,695 · 2021: $2,032 · 2022: $1,713 · 2023: $2,729 · 2024: $2,310 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,169 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,168.86 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,278.20 | 2019-2024 | Confirm Rx, Thoratec Heartmate 3 Lvas Implant Kit, Merlin@Home |
| Amgen INC. | $2,176.69 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $1,499.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $998.63 | 2022-2025 | |
| Novo Nordisk INC | $946.71 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $900.33 | 2019-2025 | Bodyguardian, Ranger, Essentio Sr |
| Janssen Pharmaceuticals, INC | $788.32 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $762.30 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.94 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $632.74 | 2019-2025 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $543.94 | 2021-2025 | Nexletol |
| Heartflow, INC. | $501.27 | 2019-2025 | |
| Tactile Systems Technology INC | $422.38 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Lilly USA, LLC | $404.51 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Medtronic, INC. | $398.80 | 2022-2024 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $386.47 | 2020-2024 | Torus Stent Graft System |
| Amarin Pharma, INC. | $270.38 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $264.55 | 2023 | Optimizer |
| Cvrx, INC. | $232.02 | 2021-2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $226.67 | 2019 | |
| Astellas Pharma US INC | $222.67 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $188.84 | 2019 | |
| Merck Sharp & Dohme LLC | $188.40 | 2021-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $180.29 | 2023-2024 | Inpefa |
| Pfizer INC. | $163.55 | 2019-2025 | |
| Philips North America LLC | $152.18 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.81 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $97.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $92.15 | 2019 | |
| Lundbeck LLC | $81.96 | 2019-2021 | |
| Edwards Lifesciences Corporation | $71.30 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $68.60 | 2023-2025 | |
| Althera Pharmaceuticals LLC | $45.18 | 2021 | |
| Kestra Medical Technology Services, INC. | $37.89 | 2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $28.59 | 2025 | Inspire |
| United Therapeutics Corporation | $26.61 | 2024 | Tyvaso |
| Resmed Corp | $19.72 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $19.17 | 2019 | |
| Cashflow Solutions, LLC | $16.61 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Alnylam Pharmaceuticals INC. | $16.42 | 2019 | |
| Normatec Industries, LP | $16.04 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.